TABLE 3.

Frequency of positive HIV-1 PBMC cultures in subjects randomized to receive triple therapy (including indinavir), according to week of therapy and plasma HIV-1 RNA concentration

Study wk	Frequency of positive PBMC culture in subjects with indicated resultsa
	Standard AMPLICOR assayb		Ultrasensitive AMPLICOR assayc
	<500 copies/ml	≥500 copies/ml	<50 copies/ml	≥50 copies/ml
8	18/34 (53)	39/44 (89)d	9/18 (50)	21/33 (64)
24	16/38 (42)	30/33 (91)	7/24 (29)	11/15 (73)
40	14/37 (38)	23/25 (92)	12/31 (39)	2/7 (29)
Total	48/109 (44)	92/102 (90)	28/73 (38)	34/55 (62)

^aNumber of subjects with positive HIV-1 PBMC cultures relative to the total number of subjects. Values in parentheses are percentages.

^bResults from seven cultures were excluded, due to missing plasma HIV-1 RNA results. The difference in the proportions of subjects who had positive PBMC cultures was significant when comparing those with HIV-1 RNA levels of <500 copies/ml and those with HIV-1 RNA levels of ≥500 copies/ml at each week (P < 0.001, Fisher's exact test).

^cThe ultrasensitive assay was performed only on samples with a standard AMPLICOR result of ≤2,000 copies/ml.

^dExcludes one culture which had indeterminate results.